The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors

Trial Profile

The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2015

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 May 2015 New trial record
    • 03 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top